Ginkgo Bioworks shares are trading higher Monday afternoon, up over 8%, following the announcement of a strategic partnership ...

Improved reporting gives greater insight into the business, but investors are still left with little visibility into potential downstream value. Ginkgo needs to demonstrate that they are more than a ...

Ginkgo Bioworks is a company with a lot of potential but also a lot of associated risk. The company is having difficulty growing revenues and is experiencing large operating losses. There are some ...

Ginkgo Bioworks (NYSE: DNA) is having a strong showing today. Specifically, the synthetic biology company's shares were up by 10.1% on heavy volume as of 9:57 a.m. ET Wednesday morning. What's behind ...

Ginkgo Bioworks announces a partnership to work with Novo Nordisk's medicines for serious chronic diseases, including diabetes and obesity. The company also announces the acquisition of AgBiome's ...

Buffett didn't get rich by buying biotechs, and his traditional value investing perspective is difficult to square with the industry's frequently unprofitable businesses. But could a company with a ...

Forbes contributors publish independent expert analyses and insights. Benjamin Wolff covers leadership insights from the world of the arts. A new technology is changing the world, turning dreams into ...

Ginkgo Bioworks Holdings ( ($DNA) ) has shared an announcement. On December 18, 2025, Ginkgo Bioworks announced that longtime co-founder and Chief ...